These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 25781031

  • 1. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study.
    Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP.
    PLoS One; 2015; 10(3):e0120290. PubMed ID: 25781031
    [Abstract] [Full Text] [Related]

  • 2. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, Virtanen MJ, Nohynek H, Jokinen J.
    Vaccine; 2018 Apr 05; 36(15):1934-1940. PubMed ID: 29526371
    [Abstract] [Full Text] [Related]

  • 3. Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.
    Palmu AA, Kilpi TM, Rinta-Kokko H, Nohynek H, Toropainen M, Nuorti JP, Jokinen J.
    Pediatrics; 2015 Jul 05; 136(1):e22-7. PubMed ID: 26077477
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland.
    Rinta-Kokko H, Auranen K, Toropainen M, Nuorti JP, Nohynek H, Siira L, Palmu AA.
    Vaccine; 2020 Feb 05; 38(6):1559-1564. PubMed ID: 31791813
    [Abstract] [Full Text] [Related]

  • 5. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA.
    Dan Med J; 2015 Jul 05; 62(7):. PubMed ID: 26183055
    [Abstract] [Full Text] [Related]

  • 6. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study.
    Palmu AA, Rinta-Kokko H, Nohynek H, Nuorti JP, Kilpi TM, Jokinen J.
    PLoS One; 2017 Jul 05; 12(3):e0172690. PubMed ID: 28249015
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.
    Peckeu L, van der Ende A, de Melker HE, Sanders EAM, Knol MJ.
    Vaccine; 2021 Jan 08; 39(2):431-437. PubMed ID: 33243632
    [Abstract] [Full Text] [Related]

  • 10. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
    Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, Otiende M, Bwanaali T, Wafula J, Mataza C, Mumbo E, Tabu C, Knoll MD, Bauni E, Marsh K, Williams TN, Kamau T, Sharif SK, Levine OS, Scott JAG.
    Lancet; 2019 May 25; 393(10186):2146-2154. PubMed ID: 31000194
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh.
    Malaker R, Hasanuzzaman M, Hooda Y, Rahman H, Chandra Das R, Kanon N, Saha S, Tanmoy AM, Ranjan Chakraborty S, Saha S, Islam M, Darmstadt GL, Baqui AH, Sathosam M, El-Arifeen S, Whitney CG, Saha SK.
    Vaccine; 2024 Jan 12; 42(2):255-262. PubMed ID: 38071104
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
    Reis JN, Azevedo J, de Oliveira AML, Menezes APO, Pedrosa M, Dos Santos MS, Ribeiro LC, Freitas HF, Gouveia EL, Teles MB, Carvalho MDG, Reis MG, Nascimento-Carvalho C, Verani JR.
    Vaccine; 2024 Jan 25; 42(3):591-597. PubMed ID: 38184393
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.
    Gidding HF, Sheridan S, Fathima P, Moore HC, Liu B, McIntyre PB, Palmu AA, ACIR Linkage Investigator Team.
    Pediatr Infect Dis J; 2019 Aug 25; 38(8):860-865. PubMed ID: 30985507
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D, Microbiologists of Epibac, ORP Networks.
    Vaccine; 2015 Jan 03; 33(2):359-66. PubMed ID: 25448105
    [Abstract] [Full Text] [Related]

  • 20. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.
    Andrade AL, Minamisava R, Policena G, Cristo EB, Domingues CM, de Cunto Brandileone MC, Almeida SC, Toscano CM, Bierrenbach AL.
    Hum Vaccin Immunother; 2016 Jan 03; 12(2):285-92. PubMed ID: 26905679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.